Trial Profile

A Randomized, Multicenter, Open-label Phase 3 Study to Compare IBI354 With or Without Pertuzumab vs. Taxane in Combination With Trastuzumab and Pertuzumab as First-line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Breast Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 354 (Primary) ; Pertuzumab (Primary) ; Docetaxel; Paclitaxel; Trastuzumab
Indications HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms HeriCare-Breast01
Sponsors Innovent Biologics

13 Feb 2026 Status changed from not yet recruiting to recruiting.
13 Feb 2026 According to the Innovent Biologics media release, the first participant has been successfully dosed in the pivotal Phase 3 clinical study (HeriCare-Breast01).
04 Feb 2026 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com